23 Jan Cellistic
Stefan Braam, Ph.D., President and Chief Technology Officer
April 10 | 11:45am | Salone dei Cavalieri, Section 2
Mont-Saint-Guibert, Belgium
(Private)
Cellistic traces its origin to a single imperative: we are accelerating allogeneic cell therapy development through reliable manufacturing processes, at lower costs. Through facilities purpose-built for that mission, we help clients simplify their cell therapy development with our iPSC-based technologies and pre-built processes, using our proprietary Pulse & Echo platforms. Our Pulse platform for cell line development provides iPSC and iPSC-based cell lines that are ready for client’s unique edits, to create product-specific working and master cell banks. Our Echo platform for cell therapy manufacturing is centered on a highly efficient family of feeder-free differentiation and expansion processes for NK cells, α/β T cells, γ/δ T cells, macrophages, and other related lineages. The combination of these two platforms ensures customers to cut years of their product development timeline at a much lower cost.
